Back to mobile site

More on RYTM

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+13.4% Growth)
- Ratings (9.0 Score)
- Holders
- FDA

Upcoming Events

- Earnings (11/3/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Rhythm Pharmaceuticals (NQ:RYTM)
Delayed: 90.21 -0.69 (0.76%)
Prev. Close $90.90  
Open$89.88 
52 Wk High$ 
52 Wk Low$ 
Day High$90.21 
Day Low$88.56 
P/E N/A  
EPS$ 
Volume97,130 

Friends, Peers and Foes (?): ABVX, CYTK, RAPP, OCUL, VRTX (more...)

Oct 21, 2026 08:00 AM Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Oct 16, 2026 03:11 AM William Blair Starts Rhythm Pharmaceuticals (RYTM) at Outperform
Oct 15, 2026 09:10 AM Rhythm Pharmaceuticals (RYTM) PT Lowered to $145 at JPMorgan
Oct 13, 2026 07:30 PM Rhythm Pharmaceuticals launches IMCIVREE in Japan for hypothalamic obesity
Oct 13, 2026 07:30 PM Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Oct 13, 2026 01:38 PM Form SCHEDULE 13G RHYTHM PHARMACEUTICALS, Filed by: JPMORGAN CHASE & CO
Oct 12, 2026 06:50 AM Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at H.C. Wainwright
Oct 8, 2026 08:27 AM Rhythm Pharmaceuticals (RYTM) PT Raised to $159 at RBC Capital
Sep 22, 2026 08:02 AM Health Canada approves Rhythm's Imcivree for hypothalamic obesity
Sep 22, 2026 08:00 AM Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
View All Articles

Entities mentioned with RYTM

View All Entities